OBJECTIVE: The concept of symptom clusters is relatively new in cancer patients' symptom management. This study, which spanned four cycles of chemotherapy, combined three commonly seen pre-treatment symptoms in cancer patients (i.e. sleep disturbances, fatigue and depression) into one symptom cluster, to explore the associations between pre-treatment cluster categories and longitudinal profiles of these same symptoms during chemotherapy. METHODS: This was a prospective study. Seventy-six women with newly diagnosed stage I-III breast cancer, scheduled to receive at least four cycles of adjuvant or neoadjuvant anthracycline-based chemotherapy participated. Data were collected at seven time points before and during treatment. Sleep quality was measured with the Pittsburgh Sleep Quality Index. Fatigue was measured with the Multidimensional Fatigue Symptom Inventory--Short Form. Depressive symptoms were measured with the Center of Epidemiological Studies--Depression. Patients were divided into three groups based on the number of symptoms they experienced before the start of chemotherapy (i.e. no symptoms, 1-2 symptoms or all three symptoms) and a symptom cluster index (SCI) was computed. RESULTS: All women reported worse sleep, more fatigue and more depressive symptoms during treatment compared with baseline (all p's<0.01); however, those women with a higher SCI (i.e. more symptoms pre-treatment) continued to experience worse symptoms during treatment compared with those who began with fewer symptoms (all p's<0.01). CONCLUSIONS: A higher clinically relevant-based pre-treatment symptom cluster was associated with more sleep disturbances, greater fatigue and more depressive symptoms during chemotherapy. Specific interventions for these pre-treatment symptoms may improve the frequency and severity of these same symptoms during chemotherapy, when they are most severe and most disruptive to quality of life. (c) 2008 John Wiley & Sons, Ltd.
OBJECTIVE: The concept of symptom clusters is relatively new in cancerpatients' symptom management. This study, which spanned four cycles of chemotherapy, combined three commonly seen pre-treatment symptoms in cancerpatients (i.e. sleep disturbances, fatigue and depression) into one symptom cluster, to explore the associations between pre-treatment cluster categories and longitudinal profiles of these same symptoms during chemotherapy. METHODS: This was a prospective study. Seventy-six women with newly diagnosed stage I-III breast cancer, scheduled to receive at least four cycles of adjuvant or neoadjuvant anthracycline-based chemotherapy participated. Data were collected at seven time points before and during treatment. Sleep quality was measured with the Pittsburgh Sleep Quality Index. Fatigue was measured with the Multidimensional Fatigue Symptom Inventory--Short Form. Depressive symptoms were measured with the Center of Epidemiological Studies--Depression. Patients were divided into three groups based on the number of symptoms they experienced before the start of chemotherapy (i.e. no symptoms, 1-2 symptoms or all three symptoms) and a symptom cluster index (SCI) was computed. RESULTS: All women reported worse sleep, more fatigue and more depressive symptoms during treatment compared with baseline (all p's<0.01); however, those women with a higher SCI (i.e. more symptoms pre-treatment) continued to experience worse symptoms during treatment compared with those who began with fewer symptoms (all p's<0.01). CONCLUSIONS: A higher clinically relevant-based pre-treatment symptom cluster was associated with more sleep disturbances, greater fatigue and more depressive symptoms during chemotherapy. Specific interventions for these pre-treatment symptoms may improve the frequency and severity of these same symptoms during chemotherapy, when they are most severe and most disruptive to quality of life. (c) 2008 John Wiley & Sons, Ltd.
Authors: M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor Journal: J Adv Nurs Date: 2001-03 Impact factor: 3.187
Authors: Paul J Mills; Barbara Parker; Vicky Jones; Karen A Adler; Christy J Perez; Sherella Johnson; Mairav Cohen-Zion; Matthew Marler; Georgia R Sadler; Joel E Dimsdale; Sonia Ancoli-Israel Journal: Clin Cancer Res Date: 2004-08-01 Impact factor: 12.531
Authors: Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Janet S Carpenter; Julie L Elam; Sheila H Ridner; Pam H Carney; Gloria J Cherry; Heather L Cucullu Journal: Oncol Nurs Forum Date: 2004-05 Impact factor: 2.172
Authors: Donald L Patrick; Sandra L Ferketich; Paul S Frame; Jesse J Harris; Carolyn B Hendricks; Bernard Levin; Michael P Link; Craig Lustig; Joseph McLaughlin; L Douglas Ried; Andrew T Turrisi; Jürgen Unützer; Sally W Vernon Journal: J Natl Cancer Inst Date: 2003-08-06 Impact factor: 13.506
Authors: Doerte U Junghaenel; Jules Cohen; Stefan Schneider; Anu R Neerukonda; Joan E Broderick Journal: Support Care Cancer Date: 2015-01-27 Impact factor: 3.603
Authors: Heather S L Jim; Paul B Jacobsen; Kristin M Phillips; Robert M Wenham; William Roberts; Brent J Small Journal: Health Psychol Date: 2013-02-25 Impact factor: 4.267
Authors: Christopher P Fagundes; Ronald Glaser; Catherine M Alfano; Jeanette M Bennett; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; Lisa D Yee; William E Carson; William B Farrar; William B Malarkey; Janice K Kiecolt-Glaser Journal: Brain Behav Immun Date: 2011-10-02 Impact factor: 7.217
Authors: William H Walker; O Hecmarie Meléndez-Fernández; Jordan L Pascoe; Ning Zhang; A Courtney DeVries Journal: Brain Behav Immun Date: 2020-07-29 Impact factor: 7.217
Authors: Kelley M Kidwell; Steven E Harte; Daniel F Hayes; Anna Maria Storniolo; Janet Carpenter; David A Flockhart; Vered Stearns; Daniel J Clauw; David A Williams; N Lynn Henry Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Kristin M Phillips; Leigh Anne Faul; Brent J Small; Paul B Jacobsen; Sachin M Apte; Heather S L Jim Journal: J Pain Symptom Manage Date: 2012-11-15 Impact factor: 3.612